Redsyvir will become the first COVID-19 drug to go into space for research

When SpaceX's CRS-21 arrives at the International Space Station this weekend, it will carry several experiments to the International Space Station in addition to resupplying astronauts and the station.
, including the first COVID-19 drug experiment set up in space.
Scientists will use the commercial ICE Cubes Service to test the COVID-19 drug in microgravity to better understand how Redsivir interacts with its delivery substance, cyclodext, to improve the drug's efficiency, according to the European Space Agency's official website.
is known to be an intravenous drug, and the experiment will not allow astronauts to receive any treatment.
will be the first COVID-19-related study to be carried out on the International Space Station.
," ESA said.
so far, there has been no broad consensus on whether Redsiwell is effective.
In October, just a week after WHO announced that drugs such as redsivir and hydroxychloroquine were "almost ineffective" in reducing the death rate from neocosmic pneumonia, the FDA officially approved Gilead's antiviral drug, Remdesivir, for use in adults and children aged 12 and older who weigh at least 40 kg and need hospitalization for COVID-19 treatment.
, the drug trial of Redsyvir is still ongoing, even as the controversy continues.
it is understood that the Redsiway space experiment will take place at ESA's Columbus laboratory, a module on the International Space Station that carries scientific and physical research.
InnoStudio, one of the experiment's customers, said in a statement in November that the team behind Redsivir's study on the International Space Station hopes it will make the drug more effective and reduce the risk of kidney problems in patients with kidney problems.
。